SK pharmteco
skpharmteco.com
Manufacturing
Biotechnology
As featured in
Claim pageClaim
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Total raised
$260M
1 round on record
Latest round
$260M
Venture round · Sep 2024 · 2 yr ago
The money's age
Due for its next round
24 months since the last round · not hiring
Momentum
15/100
in the news
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Sep 24
Launched SK pharmteco Launches Catalyst Kit to Streamline Catalytic Reaction Development and Continuous Manufacturing Scale-Up · skpharmteco.com
Sep 30, 2024
Raised a round Venture round $260M · Pulse 2.0
Nov 1, 2022
New executive SK pharmteco appoints Joerg Ahlgrimm as CEO to spearhead the next phase of company growth and innovation · PRNewswire
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Venture round | Sep 2024 | $260M | — | Pulse 2.0 |
Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
Discover 64xBio's end-to-end platform for next-generation biologics. We enable scalable therapeutic systems through VectorSelect™…
Light Horse is a small molecule drug discovery company that is leading the way in a.
Avicenna Biosciences is a drug development company using machine learning-enhanced medicinal chemistry to accelerate the lead-to-candidate…
Aragen is a fully integrated, technology-led CRDMO supporting discovery, development and manufacturing for small molecules and biologics.
Abinitio bio is the AI-native operating platform for drug development and manufacturing.
Instant Quantification of genetic modifications for Cell and Gene Therapies.
News
From Facility to Delivery: Solving the Complex Science of ADC Linker-Payload Synthesis
Practical strategies for developing, scaling, and manufacturing highly potent ADC linker-payloads As antibody-drug conjugate (ADC) programs advance, highly potent linker-payloads create manufacturing challenges that extend beyond chemistry alone. Material
Read more
Report
Solvent Recovery Systems for Sustainable Pharmaceutical Manufacturing
Practical strategies for evaluating, recovering, and reusing solvents across pharmaceutical manufacturing Solvents can represent a significant portion of pharmaceutical production mass and contribute substantially to manufacturing waste. Recovering and re
Read more
Report
Crude Peptide Purification Optimization for Scalable Manufacturing
Case Study: Rapid Purification Process Development for Challenging Crude Peptide Streams Peptide purification can become a significant development challenge when crude material exhibits poor solubility, limited stability, aggregation, or gelling behavior.
Read more
Report
SKyvec Lenti for In Vivo Applications
Case Study: Scalable Manufacturing for Systemic Lentiviral Gene Delivery In Vivo lentiviral vectors (LVVs) are administered directly to patients as the final drug product, increasing quality expectations for purity, potency, characterization, manufacturin
Read more
Report
Simplifying Adenoviral Purification for Scalable Manufacturing
Adenoviral vectors are widely used across gene therapy, oncolytic therapies, and vaccines, but downstream purification remains a primary constraint on yield, cost, operational efficiency, and manufacturing scalability. Traditional multi-step chromatograph
Read more
Report
Extractables and Leachables Enter a New Regulatory Phase
How ICH Q3E and USP / are broadening E&L expectations across pharmaceutical manufacturing Extractables and leachables (E&L) assessments are moving beyond traditional container-closure testing toward a broader, risk-based approach that considers materials
Read more
Report
SK pharmteco Announces $200-Plus Million U.S. Investment to Expand Small Molecule and Peptide Capacity
RANCHO CORDOVA, Calif., Sept. 30, 2026 (GLOBE NEWSWIRE) -- SK pharmteco today announced a comprehensive five-year, more than $200 million investment plan to expand and upgrade its U.S. development and manufacturing infrastructure across small molecules an
Read more
Report
SK pharmteco Announces $200-Plus Million U.S. Investment to Expand Small Molecule and Peptide Capacity
FOR IMMEDIATE RELEASE Rancho Cordova, CA (September 29, 2026) - SK pharmteco today announced a comprehensive five-year, more than $200 million investment plan to expand and upgrade its U.S. development and manufacturing infrastructure across small molecul
Read more
Report
SK pharmteco Launches Catalyst Kit to Streamline Catalytic Reaction Development and Continuous Manufacturing Scale-Up
RANCHO CORDOVA, Calif., Sept. 24, 2026 (GLOBE NEWSWIRE) -- SK pharmteco today announced the launch of the SK pharmteco Catalyst Kit, a structure...
Read more
Report
SK pharmteco Launches Catalyst Kit to Streamline Catalytic Reaction Development and Continuous Manufacturing Scale-Up
FOR IMMEDIATE RELEASE New structured offering bridges the gap between catalyst screening, process optimization, and commercial-scale continuous flow manufacturing for RSMs, Intermediates, and APIs Rancho Cordova, CA (September 24, 2026) - SK pharmteco tod
Read more
Report
Show more news
Offices
Where the company hires and what each office is for
Cities
4
Hiring now
0
Countries
3
Loading the map
Headquarters
Builds here
Office with open vacancies
No open vacancies right now Tap a pin for the office
Rancho Cordova
United States
HQ
Our locations
12295 Hartford St, Rancho Cordova, California 95742, USA
Corbeil-Essonnes
France
Regional office
Analytical Services Facility
26 Rue Henri Auguste Desbruères, 91100 Corbeil-Essonnes, France
King of Prussia
United States
Plant / site
Small Molecule Manufacturing Plant
411 Swedeland Rd #100, King of Prussia, PA 19406, United States
Swords
Ireland
Plant / site
Viral Vector Manufacturing Plant
Swords Campus, Watery Lane, Swords, Co. Dublin. K67 AY91, Ireland
Financials
Total raised
$260M
Latest round
Venture - Series Unknown
Funding rounds
1
Funding rounds
| Round | Announced | Amount | |
|---|---|---|---|
| Venture - Series Unknown | 2024 | $260M | Details |